Exelixis rose 78.3% in a year. Moderna rose 10.5-fold.

Same industry

EXEL against four biotech peers, a year at 100

EXEL is up 78.3% in a year. Moderna is up 10.5 times. Of these four, Biogen (+63.6%), Amgen (+49.4%) and Gilead Sciences (+46.8%) did less. Weekly closes, Nov 7, 2025 = 100, on a log scale so a 10.5-fold rise and a 46.8% rise both read honestly.

Share this chart

EXEL +78.3%. Moderna ×10.5, Biogen +63.6%, Amgen +49.4%, Gilead Sciences +46.8%. Weekly closes, Nov 7, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in EXEL’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

EXEL: stories, the record and filings →